Skip to content

Study · Non-randomized trial · n = 25 · 1982

4 results

The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female.

Hilton P, Stanton SL

British journal of urology1 Jun 1982Cited by 64 (Europe PMC)

PMID7049302 (opens in a new tab)DOI10.1111/j.1464-410x.1982.tb06969.x (opens in a new tab)PepBankPUB-07049302
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with nocturia, DDAVP reduced nocturnal urinary frequency to 1.9 episodes versus 2.6 with placebo.

    In plain wordsIn patients with nocturia, DDAVP reduced nighttime urination more than placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturnal urinary frequency versus placebo
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Nocturnal frequency
    3.2 episodes
    baseline
    Nocturnal frequency
    2.6 episodes
    placebo
    Nocturnal frequency
    1.9 episodes
    DDAVP

    Source sentences

    Summary
    Nocturnal urinary frequency was reduced from a mean of 3.2 episodes to 2.6 with placebo and 1.9 with DDAVP (0.01 greater than P greater than 0.001).
    2 context sentences
    Summary · context
    Twenty-five patients complaining of nocturia completed a double-blind cross-over trial using desmopressin (DDAVP) and placebo.
    Summary · context
    The drugs were given as a single intranasal dose on retiring.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with nocturia, mean nocturnal urinary frequency fell from 3.2 to 1.9 episodes with DDAVP, and also fell to 2.6 episodes with placebo.

    In plain wordsIn patients with nocturia, nighttime urination fell from baseline with DDAVP, and it also fell with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturnal urinary frequency versus baseline
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Nocturnal frequency
    3.2 episodes
    baseline
    Nocturnal frequency
    1.9 episodes
    DDAVP
    Nocturnal frequency
    2.6 episodes
    placebo

    Source sentences

    Summary
    Nocturnal urinary frequency was reduced from a mean of 3.2 episodes to 2.6 with placebo and 1.9 with DDAVP (0.01 greater than P greater than 0.001).
    2 context sentences
    Summary · context
    Twenty-five patients complaining of nocturia completed a double-blind cross-over trial using desmopressin (DDAVP) and placebo.
    Summary · context
    The drugs were given as a single intranasal dose on retiring.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with nocturia, DDAVP did not significantly affect diurnal urinary symptoms.

    In plain wordsIn patients with nocturia, DDAVP did not significantly affect daytime urinary symptoms.

    Peptide
    Desmopressin
    Outcome
    No significant changeDiurnal urinary symptoms
    Study

    n = 25

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Diurnal urinary symptoms were not significantly affected and side effects were minimal.
    2 context sentences
    Summary · context
    Twenty-five patients complaining of nocturia completed a double-blind cross-over trial using desmopressin (DDAVP) and placebo.
    Summary · context
    The drugs were given as a single intranasal dose on retiring.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with nocturia, side effects during DDAVP treatment were minimal.

    In plain wordsIn patients with nocturia, side effects during DDAVP treatment were minimal.

    Peptide
    Desmopressin
    Outcome
    Not applicableSide effects
    Study

    n = 25

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Diurnal urinary symptoms were not significantly affected and side effects were minimal.
    2 context sentences
    Summary · context
    Twenty-five patients complaining of nocturia completed a double-blind cross-over trial using desmopressin (DDAVP) and placebo.
    Summary · context
    The drugs were given as a single intranasal dose on retiring.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.